Bottom line
Is MSSLX a good fund? The bottom line
MSSLX is the Class L share class of Inception Portfolio, an actively managed large blend mutual fund from Morgan Stanley.
It charges 1.85% — about $185 a year on every $10,000 invested, more expensive than 91% of large blend funds we track.
It returned +0.2% over one year, −5.4% a year over five years, +11.8% a year over ten (as of Dec 31, 2025, per its prospectus).
With $282 million in net assets and 70 holdings, its largest position is agilon health Inc (9.1%) and the top 10 make up 55.5% of the portfolio.
What stands out
- No front-end sales load
What to watch
- Expensive for its category (1.85%)
- 5-year return in the bottom quarter of its category
- Concentrated: top 10 holdings are 55.5% of assets
- 12b-1 marketing fee of 0.75% a year
Updated Nov 19, 2026
What MSSLX invests in
The Inception Portfolio (the Fund) seeks long-term capital appreciation by investing primarily in growth-oriented equity securities of small capitalization companies.
Under normal market conditions, the Adviser seeks to achieve the Funds investment objective by investing primarily in established and emerging companies with capitalizations within the range of companies included in the Russell 2000 Growth Index. As of December 31, 2025 , these market capitalizations ranged between $ 13.7 million and $ 26.0 billion. The Adviser emphasizes a bottom-up stock selection process, seeking attractive investments on an individual company basis. In selecting securities for investment, the Adviser typically invests in unique companies it believes have sustainable competitive advantages with above average business visibility, the ability to deploy capital at high rates of return, strong balance sheets and an attractive risk/reward. The Adviser typically focuses a significant portion of the Funds investments in a limited number of issuers, which may be in the same…
From the fund's prospectus (filed Apr 30, 2026).
MSSLX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| MSSLX | +0.2% | −5.4% | +11.8% |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What MSSLX costs
On a $10,000 investment, MSSLX's 1.85% expense ratio costs about $185 a year. The prospectus estimates $2,759 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
MSSLX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | agilon health Inc | 9.10% |
| 2 | Cloudflare Inc | 8.95% |
| 3 | Opendoor Technologies Inc | 7.38% |
| 4 | Aurora Innovation Inc | 6.57% |
| 5 | IonQ Inc | 5.88% |
| 6 | X4 Pharmaceuticals Inc | 3.82% |
| 7 | HealthEquity Inc | 3.61% |
| 8 | Celsius Holdings Inc | 3.53% |
| 9 | Immunovant Inc | 3.44% |
| 10 | GRAIL Inc | 3.19% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 55.5% of the fund. See all top 25 holdings and asset mix →